Rocket Pharmaceuticals Inc（RCKT）财务数据RCKTRocket Pharmaceuticals Inc

Evaluating the bottom line, Rocket Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -4.77%, provide a clear picture of how effectively RCKT converts its operational activities into shareholder value.

In the context of the broader market, RCKT competes directly with industry leaders such as BIOA and IPSC. With a market capitalization of $286.50M, it holds a significant position in the sector. When comparing efficiency, RCKT's gross margin of N/A stands against BIOA's 100.00% and IPSC's N/A. Such benchmarking helps identify whether Rocket Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The company's recent financials show a significant turnaround with a net income of $123.21 million in Q2 2026, compared to losses in previous quarters. This shift indicates potential for future profitability as clinical trials progress.